Small molecule · Inhibitor of Cyclooxygenase (prostaglandin-endoperoxide synthase) (PTGS1) and Cyclooxygenase-2 (PTGS2) · developed by Bayer
Aspirin is an orally given non-steroidal anti-inflammatory small molecule that acetylates serine residues in cyclooxygenase enzymes, reducing prostaglandin synthesis and platelet aggregation. It is studied in prostate cancer, germ cell and testicular cancers, chronic myeloid leukemia, and venous thromboembolism.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07213778 | Phase 3 | Symptomatic Venous Thromboembolism (VTE) | Recruiting | REGN |
| NCT06866964 | Phase 2 | Germ Cell Tumor | Recruiting | RNA |
| NCT03899987 | Phase 2 | Prostate Adenocarcinoma | Active not recruiting | AIM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Germ Cell TumorProstate AdenocarcinomaStage I Prostate Cancer AJCC v8Stage II Prostate Cancer AJCC v8Stage IIA Prostate Cancer AJCC v8Stage IIB Prostate Cancer AJCC v8Stage IIC Prostate Cancer AJCC v8Stage III Prostate Cancer AJCC v8Stage IIIA Prostate Cancer AJCC v8Stage IIIB Prostate Cancer AJCC v8Stage IIIC Prostate Cancer AJCC v8Symptomatic Venous Thromboembolism (VTE)Testicular CancerChronic Myeloid Leukemia, Chronic Phase
Updated Nov 8, 2026.